Analysts Have Conflicting Sentiments on These Healthcare Companies: Sarepta Therapeutics (SRPT), Insmed (INSM) and Carlsmed, Inc. (CARL)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT – Research Report), Insmed (INSM – Research Report) and Carlsmed, Inc. (CARL – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sarepta Therapeutics (SRPT)
Goldman Sachs analyst Salveen Richter maintained a Hold rating on Sarepta Therapeutics yesterday and set a price target of $17.00. The company’s shares closed last Wednesday at $18.97.
According to TipRanks.com, Richter is a 4-star analyst with an average return of
Sarepta Therapeutics has an analyst consensus of Hold, with a price target consensus of $21.94, representing a 16.3% upside. In a report released today, Morgan Stanley also maintained a Hold rating on the stock with a $20.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Insmed (INSM)
Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on Insmed today and set a price target of $204.00. The company’s shares closed last Wednesday at $148.61.
According to TipRanks.com, Suvannavejh is a 5-star analyst with an average return of
Insmed has an analyst consensus of Strong Buy, with a price target consensus of $217.29, implying a 36.0% upside from current levels. In a report issued on February 16, Roth MKM also maintained a Buy rating on the stock with a $212.00 price target.
Carlsmed, Inc. (CARL)
BTIG analyst Ryan Zimmerman reiterated a Buy rating on Carlsmed, Inc. today and set a price target of $24.00. The company’s shares closed last Wednesday at $12.56.
According to TipRanks.com, Zimmerman is a 2-star analyst with an average return of
Currently, the analyst consensus on Carlsmed, Inc. is a Strong Buy with an average price target of $19.67, implying a 50.4% upside from current levels. In a report released today, Bank of America Securities also reiterated a Buy rating on the stock with a $17.00 price target.
